Hearing:
“Assessing VA’s Risks for Drug Diversion”
Subcommittee on Oversight and Investigations (Committee on Veterans' Affairs)
Monday, February 27, 2017 (3:30 PM)
334 CHOB
Washington, D.C.
Witnesses
Carolyn Clancy, M.D.
Deputy Under Secretary for Health for Organizational Excellence, Veterans Health Administration, on behalf of U.S. Department of Veterans Affairs
Added
02/23/2017 at 09:06 AM
- Witness Statement
[PDF]
Added
02/27/2017 at 05:27 PM
Michael H. Valentino, R. Ph. , MHSA
(Accompanying Dr. Lynch) Chief Consultant, Veterans Health Administration, Pharmacy Benefits Management Services, on behalf of U.S. Department of Veterans Affairs
Added
02/22/2017 at 11:54 AM
Nick Dahl
Deputy Assistant Inspector General for Audits and Evaluations, on behalf of VA Office of Inspector General
Added
02/22/2017 at 11:54 AM
- Witness Statement
[PDF]
Added
02/27/2017 at 05:27 PM
Emorfia Valkanos, R. Ph.
(Accompanying Mr. Dahl) Health Systems Specialist, Office of Healthcare Inspections, on behalf of VA Office of Inspector General
Added
02/22/2017 at 11:54 AM
Randall B. Williamson
Director, Healthcare Team, U.S. Government Accountability Office, on behalf of U.S. Government Accountability Office
Added
02/22/2017 at 11:54 AM
- Witness Statement
[PDF]
Added
02/27/2017 at 05:27 PM
Keith Berge, M.D.
Consultant in Anesthesiology, Chair, Mayo Clinic Enterprise-wide Medication Diversion Prevention Committee, on behalf of Mayo Clinic
Added
02/22/2017 at 11:54 AM
- Witness Statement
[PDF]
Added
02/27/2017 at 05:27 PM
- Witness Disclosure
[PDF]
Added
02/23/2017 at 09:06 AM
Support Documents
- Statement for the Record, American Society of Anesthesiologists
[PDF]
Added
02/27/2017 at 01:47 PM
- Final Witness List
[PDF]
Added
02/27/2017 at 01:47 PM
Hearing Record
- Final Printed Hearing
[PDF]
Added
06/05/2018 at 11:27 AM
First Published:
February 15, 2017 at 04:43 PM
Last Updated:
June 5, 2018 at 11:27 AM